Specialist in Marketing Research with over 19 years experience in the Clinical Research and Pharmaceutical Industry. Presently at Lambda since 8 years as a member of the International Business Development Team; Engaged in business meetings with various Stakeholders and clients Across the globe. Successfully accomplishing project deliverables in many various services like Bioequivalence, Bioanalytical, Phase I – IV , Pharmacovigilance as per Clients expectations and business requirements.
Mr. Tully brings to Lambda over 25 year’s experience in Business Development, with the last 12+ years in the clinical research domain. His experience has focused on Bioequivalence and Bioavailability studies, Phase I, Phase II-IV trials and Pharmacovigilance.
Mr. Tully credits his success to building lasting business relationships with clients in North America, Europe, and Asia. He has extensive experience identifying and developing new business opportunities. Integrity, respect for others and a diligent work ethic, has contributed greatly to his long term success.
Prior to entering the Clinical Research industry, Richard spent several years in financial services after earning his Series 8 Securities License, and also spent several years in Business Development for a medical device company.
Dr. Dal Rio has extensive experience of 20 years in different sectors like QA, R&D, Project Management in CRO Industry. He is an experienced Sales Director with more than 10 years of experience and skilled professional with the knowledge of Biotechnology, Good Laboratory Practice (GLP), Drug Discovery, Pharmacology, Preclinical and Clinical Development, Sales and Life Sciences. Strong sales professional with MSc. in Biological Science focused in Biology from Università degli Studi di Roma - Tor Vergata.
Presently Dr. Dal Rio is part of the Lambda Global Sales Team as Director – European Business Development, Focusing on European Market for Lambda Therapeutics portfolio.
Mr. Gandhi is part of the senior management team of Novum and associated since 2004.
His expertise in sales and marketing saw him ascend into a leadership role and he was early to recognize the opportunity to target Indian pharmaceutical companies who were growing in size and number, as they began looking to the US market to sell their products. Novum soon became the go-to CRO for Indian generic companies seeking FDA product approvals for the US as the generic industry exploded and worked tirelessly to further augment business which drove rapid and large growth in Novum’s revenues.
A consummate relationship builder, Mr Gandhi forged excellent relationships with senior pharma professionals and companies that continue to thrive today. Mr Gandhi has worked in recent years to target new companies and move beyond generic drug services, tapping NCE and 505(b)(2) targets at existing and new companies.
Mr. Gandhi moved from India to the US in 1976, settling in Pittsburgh at Novum’s headquarters and is a BS in Biology and Masters in Chemistry from Bombay University.